Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.

Journal of lipid research - 1 Feb 2010

Yang Shao H, Chang Sandy Y, Andres Douglas A, Spielmann H Peter, Young Stephen G, Fong Loren G

Abstract excerpt

Hutchinson-Gilford progeria syndrome (HGPS) is caused by the accumulation of a farnesylated form of prelamin A (progerin). Previously, we showed that blocking protein farnesylation with a farnesyltransferase inhibitor (FTI) ameliorates the disease phenotypes in mouse model of HGPS (Lmna(HG/+)). H...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adipose Tissue
Share to Body Weight
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Farnesyltranstransferase

Share to Fibroblasts

Share to Imidazoles

Share to Progeria

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 19965595
DOI: 10.1194/jlr.M002808
PMCID: PMC2803242

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19965595-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.PMID 19965595Read ↗

Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated.Semantic proximity Read ↗

Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.Semantic proximity Read ↗

Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.Semantic proximity Read ↗

Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson–Gilford Progeria SyndromeSemantic proximity Read ↗

A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.Semantic proximity Read ↗

Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele.Semantic proximity Read ↗

New approaches to progeria.Semantic proximity Read ↗

Hutchinson-Gilford Progeria paves the way for novel targeted anti-aging therapies.Semantic proximity Read ↗

Hutchinson-Gilford Progeria Syndrome—Current Status and Prospects for Gene Therapy TreatmentSemantic proximity Read ↗

Progerin, an Aberrant Spliced form of Lamin A, is a Potential Therapeutic Target for HGPSSemantic proximity Read ↗

Progerinin, an Inhibitor of Progerin, Alleviates Cardiac Abnormalities in a Model Mouse of Hutchinson-Gilford Progeria Syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.